In lung cancer, sHLA-G in plasma discriminated non-small-cell lung cancer (NSCLC) from small-cell lung cancer (SCLC) and served as a prognostic marker with high levels of sHLA-G indicating reduced overall survival (OS). Here, HLA-G is linked to small cell lung carcinoma.